title: Brentuximab vedotin.
abstract: Brentuximab vedotin (cAC10-vcMMAE; SGN 35; SGN-35) is an anticancer antibody-drug conjugate under development by Seattle Genetics Inc. and its licensee Millennium: The Takeda Oncology Company. It comprises the anti-CD30 monoclonal antibody cAC10 conjugated to the cytotoxic agent monomethyl auristatin E, a synthetic analog of the tubulin polymerization inhibitor dolastatin 10. It is under investigation for use in Hodgkin lymphoma and non-Hodgkin lymphoma (specifically anaplastic large cell lymphoma) in North America and Europe. This review discusses the key development milestones and therapeutic trials of this drug.
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D004354:Drug Screening Assays, Antitumor; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology / Q000627:therapeutic use*; D000922:Immunotoxins / Q000494:pharmacology / Q000627:therapeutic use*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000922:Immunotoxins; D000079963:Brentuximab Vedotin